ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 227 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $156,758 | -17.0% | 28,763 | +2.1% | 0.00% | -50.0% |
| Q2 2023 | $188,960 | -26.2% | 28,161 | -2.9% | 0.00% | 0.0% |
| Q1 2023 | $256,123 | +18.8% | 29,006 | +2.8% | 0.00% | 0.0% |
| Q4 2022 | $215,601 | +11.7% | 28,220 | +4.3% | 0.00% | 0.0% |
| Q3 2022 | $193,000 | -11.1% | 27,055 | +0.7% | 0.00% | 0.0% |
| Q2 2022 | $217,000 | -36.9% | 26,859 | +8.3% | 0.00% | -33.3% |
| Q1 2022 | $344,000 | -50.2% | 24,798 | +0.7% | 0.00% | -40.0% |
| Q4 2021 | $691,000 | -18.1% | 24,626 | -0.9% | 0.01% | -28.6% |
| Q3 2021 | $844,000 | -16.0% | 24,843 | +1.0% | 0.01% | -12.5% |
| Q2 2021 | $1,005,000 | -3.6% | 24,598 | -5.0% | 0.01% | -11.1% |
| Q1 2021 | $1,042,000 | -31.2% | 25,880 | +1.1% | 0.01% | -35.7% |
| Q4 2020 | $1,514,000 | +35.5% | 25,598 | +11.4% | 0.01% | +27.3% |
| Q3 2020 | $1,117,000 | +34.9% | 22,971 | +34.3% | 0.01% | -8.3% |
| Q2 2020 | $828,000 | – | 17,107 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |